The stock of Omeros Corporation (NASDAQ:OMER) is a huge mover today! About 1.30 million shares traded hands or 50.72% up from the average. Omeros Corporation (NASDAQ:OMER) has declined 35.27% since April 8, 2016 and is downtrending. It has underperformed by 40.92% the S&P500.
The move comes after 8 months positive chart setup for the $551.83M company. It was reported on Nov, 10 by Barchart.com. We have $15.17 PT which if reached, will make NASDAQ:OMER worth $160.03 million more.
Analysts await Omeros Corporation (NASDAQ:OMER) to report earnings on November, 14. They expect $-0.30 EPS, up 34.78% or $0.16 from last year’s $-0.46 per share. After $-0.24 actual EPS reported by Omeros Corporation for the previous quarter, Wall Street now forecasts 25.00% negative EPS growth.
Omeros Corporation (NASDAQ:OMER) Ratings Coverage
Out of 6 analysts covering Omeros (NASDAQ:OMER), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Omeros has been the topic of 11 analyst reports since August 10, 2015 according to StockzIntelligence Inc. On Monday, August 10 the stock rating was initiated by Roth Capital with “Buy”. The rating was maintained by Needham on Wednesday, November 11 with “Buy”. The rating was maintained by Needham with “Buy” on Thursday, November 10. The stock of Omeros Corporation (NASDAQ:OMER) earned “Buy” rating by Needham on Monday, August 31. The firm has “Outperform” rating given on Tuesday, August 18 by Cowen & Co. TH Capital initiated it with “Buy” rating and $38.0 target price in Monday, August 10 report. As per Friday, June 3, the company rating was initiated by Cantor Fitzgerald. WBB Securities maintained it with “Strong Buy” rating and $75 target price in Tuesday, August 18 report.
According to Zacks Investment Research, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.”
Insitutional Activity: The institutional sentiment decreased to 0.77 in Q2 2016. Its down 0.21, from 0.98 in 2016Q1. The ratio is negative, as 15 funds sold all Omeros Corporation shares owned while 32 reduced positions. 13 funds bought stakes while 23 increased positions. They now own 19.91 million shares or 14.90% more from 17.33 million shares in 2016Q1.
Brighton Jones Ltd Company last reported 13,218 shares in the company. Allianz Asset Management Ag accumulated 109,278 shares or 0% of the stock. Schwab Charles Investment accumulated 65,900 shares or 0% of the stock. The New Jersey-based Financial Architects Incorporated has invested 0% in Omeros Corporation (NASDAQ:OMER). Alliancebernstein Lp holds 0% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 54,000 shares. Chicago Equity Prtnrs Lc last reported 0.03% of its portfolio in the stock. Natl Bank Of America Corp De has 69,311 shares for 0% of their US portfolio. Teacher Retirement Sys Of Texas, a Texas-based fund reported 5,024 shares. Pnc Fincl Svcs Gp Inc accumulated 0% or 224 shares. Great West Life Assurance Can holds 3,347 shares or 0% of its portfolio. Gradient Invests Lc accumulated 0.03% or 24,471 shares. Swiss Savings Bank holds 0% or 57,300 shares in its portfolio. Goldman Sachs Grp has invested 0% of its portfolio in Omeros Corporation (NASDAQ:OMER). Gru One Trading Limited Partnership, a Illinois-based fund reported 8,161 shares. Millennium Management Limited Liability Co holds 0% or 15,362 shares in its portfolio.
Insider Transactions: Since May 16, 2016, the stock had 0 insider buys, and 5 sales for $732,521 net activity. $158,057 worth of Omeros Corporation (NASDAQ:OMER) was sold by Kelbon Marcia S. on Monday, May 16. Cable Thomas J. sold $34,557 worth of stock.
More important recent Omeros Corporation (NASDAQ:OMER) news were published by: Businesswire.com which released: “Omeros Corporation to Announce Third Quarter 2016 Financial Results on …” on November 07, 2016, also Businesswire.com published article titled: “Omeros Announces Completion of Initial Funding under $125 Million Credit Facility”, Seekingalpha.com published: “Encouraging News From Omeros Corporation” on October 18, 2016. More interesting news about Omeros Corporation (NASDAQ:OMER) was released by: Seekingalpha.com and their article: “Omeros: Funding Resolved, Reset Expectations For Omidria” with publication date: November 08, 2016.
OMER Company Profile
Omeros Corporation, incorporated on June 16, 1994, is a biopharmaceutical company. The Firm is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is launched in the United States for use during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from the Company’s PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. The Company’s PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.